evipedia.ai
← Back

Tadalafil for Health & Longevity

Evidence Review created on 11/04/2026 using AI4L / Opus 5.5

Also known as: Cialis, Cialis Together, Adcirca, Alyq, Tadliq, IC351, GF196960

Motivation

Tadalafil (Cialis) is a prescription oral medication that widens blood vessels and relaxes the muscle of the prostate and bladder outlet. It works by blocking an enzyme that normally switches off the body’s own vessel-widening signal. It is best known as a long-acting treatment for erectile problems and for the urinary symptoms of an enlarged prostate, and it is now inexpensive and widely available as a generic.

Interest among health-focused adults has grown for two reasons. The drug’s long duration of action allows a small, steady daily dose, and sexual and urinary function often decline together with age. Large health-record studies have also examined whether long-term users differ from non-users in heart disease and overall survival, which has drawn attention to tadalafil well beyond its approved uses.

This review examines the evidence for and against using tadalafil for health and longevity: its established and proposed benefits, its side effects and interactions, dosing and monitoring, and how much of the case rests on controlled trials rather than health records.

Benefits - Risks - Protocol - Conclusion

This section lists high-level expert content on tadalafil, PDE5 (phosphodiesterase type 5, the enzyme tadalafil blocks) inhibition and longevity.

Only four items are listed because no further content qualified. No relevant content was found from Rhonda Patrick (FoundMyFitness) or Chris Kresser: on-site and web searches returned no material on tadalafil or PDE5 inhibitors. Lifespan.io’s only tadalafil match was a news summary of a rat resveratrol study with a tadalafil add-on arm, which does not give an overview of tadalafil.

Grokipedia

  • Tadalafil

    A broad overview of tadalafil’s indications, pharmacokinetics (17.5-hour half-life, clearance by CYP3A4 (a liver enzyme that metabolizes about half of all drugs)), dosing strengths and brand names, useful as a quick factual reference.

Examine

No Examine article on tadalafil exists. Examine.com does not typically cover prescription medications, and its site search returned no results for tadalafil.

ConsumerLab

No ConsumerLab article on tadalafil exists. ConsumerLab does not typically cover prescription medications; tadalafil appears there only in a member Q&A on supplement interactions and in recall notices for supplements adulterated with undeclared tadalafil.

Systematic Reviews

This section lists systematic reviews and meta-analyses covering tadalafil’s main claimed benefits and its principal long-term risk concern.

Mechanism of Action

Tadalafil selectively inhibits PDE5, the enzyme that breaks down cGMP (cyclic guanosine monophosphate, an internal messenger that relaxes smooth muscle). Nitric oxide (NO, a gas signal released by nerves and the inner lining of blood vessels) triggers cGMP production; by slowing its breakdown, tadalafil amplifies existing NO signaling rather than creating it. Erections therefore still require sexual stimulation, and effects in the prostate, bladder neck, lung arteries and systemic arteries depend on local NO activity.

Key properties (manufacturer Eli Lilly’s US Food and Drug Administration (FDA) label, FDA label):

  • Half-life: mean 17.5 hours; steady state within 5 days of daily dosing
  • Selectivity: 700-fold for PDE5 over PDE6 (the retinal enzyme for light detection), explaining rare color-vision changes; only 14-fold over PDE11A1 (an enzyme in muscle, prostate and testis), a proposed contributor to back pain
  • Tissue distribution: apparent volume of distribution about 63 L, indicating tissue penetration; 94% protein-bound; peak level at a median of 2 hours, unaffected by food
  • Metabolism: predominantly CYP3A4 to an inactive catechol metabolite; excreted 61% in feces and 36% in urine

Competing explanations exist for the longevity case. Supporters point to improved endothelial function (vessel-lining relaxation) and reduced vascular inflammation from sustained cGMP signaling; skeptics attribute mortality signals to a healthy-user effect, since men prescribed tadalafil tend to be healthier. On the harm side, cGMP-linked activation of the MAPK pathway (a cell-growth signaling cascade) in pigment cells has been proposed to explain melanoma associations, though causality is unproven.

Historical Context & Evolution

Chemists at Glaxo Wellcome identified the compound, coded IC351, while seeking selective PDE5 inhibitors in the 1990s and first characterized it as a blood-pressure-lowering agent in hypertensive rats (Daugan 2003). It was later developed with ICOS and Eli Lilly as an erectile dysfunction treatment distinguished from sildenafil by its long duration of action; the US approval for Cialis dates from 2003 (FDA label). Indications later expanded to urinary symptoms of prostate enlargement and, under the Adcirca brand, to pulmonary arterial hypertension (PAH, high blood pressure in the lung arteries that strains the right heart) (UK Summary of Product Characteristics, Adcirca SmPC).

Interest for health optimization grew from three observations: erectile dysfunction often precedes cardiovascular disease, daily low doses keep blood levels steady, and large claims-database cohorts reported lower cardiovascular events and mortality among users (Kloner 2024, led by a paid consultant to Sanofi, which holds Cialis over-the-counter rights). Generic availability made long-term daily use inexpensive.

Scientific opinion has shifted in both directions. Hopes for broader uses were tempered when a 48-week trial in Duchenne muscular dystrophy (an inherited muscle-wasting disease) found no benefit (Victor 2017; FDA label). A dementia signal from sildenafil records (Fang 2021) prompted tadalafil studies, but a Medicare analysis comparing drug classes in pulmonary hypertension patients found no association (Desai 2022), while a large UK cohort comparing men with erectile dysfunction against non-users found one (Adesuyan 2024). Because tadalafil is off-patent, little commercial incentive exists to fund long outcome trials, so the longevity question remains open.

Expected Benefits

High 🟩 🟩 🟩

Erectile Function

Tadalafil restores erection quality in men with erectile dysfunction (ED, persistent inability to achieve or keep an erection) of vascular, diabetic and psychological causes, taken on demand (10–20 mg) or daily (2.5–5 mg). Evidence comes from integrated randomized controlled trial (RCT) analyses led by Brock (Brock 2002; 5 trials, 1,112 men) and Porst (6 trials, 1,913 men), both sponsored by manufacturer Eli Lilly, and an independent government-funded meta-analysis by Tsertsvadze. For this audience, erectile function is also an early vascular-health signal, so a good response does not replace cardiovascular evaluation.

Magnitude: Successful intercourse in 69% of attempts with PDE5 inhibitors versus 35% with placebo (Tsertsvadze 2009); once-daily 5 mg improved the IIEF (International Index of Erectile Function, a 0–30 questionnaire) erectile-function score by 5.4 points versus placebo (Porst 2014).

Lower Urinary Tract Symptoms of Prostate Enlargement

Daily 5 mg relaxes prostate and bladder-neck smooth muscle, easing lower urinary tract symptoms (LUTS: frequency, urgency, weak stream, night-time urination) from benign prostatic hyperplasia (BPH, non-cancerous prostate enlargement). Lilly-sponsored RCTs led by Roehrborn (Roehrborn 2008; 1,058 men) and Oelke (511 men, with tamsulosin as active control) show improvement within 1–4 weeks, and a meta-analysis led by Gacci confirms it at 12 weeks; unlike tamsulosin, tadalafil also improves erections. Gains in urinary flow rate are small or absent in several trials.

Magnitude: IPSS (International Prostate Symptom Score, 0–35) improved 2.1 points more than placebo at 12 weeks (Oelke 2012); across PDE5 inhibitor trials, 2.8 points more than placebo (Gacci 2012).

Ureteral Stone Passage ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

This bears on acute stone episodes, not on healthy aging. By relaxing ureteral smooth muscle, tadalafil helps distal ureteral stones of 5–10 mm pass. Meta-analyses of mostly small RCTs led by Bai (6 trials, 921 patients) and Belkovsky (11 trials, 1,330 patients) found higher expulsion rates than with tamsulosin (an alpha-blocker, a drug that relaxes prostate and vessel muscle by blocking adrenaline receptors), whereas a four-trial meta-analysis led by Montes Cardona found no difference. Net reading: tadalafil aids passage, and the larger pooled analyses favor it over tamsulosin.

Magnitude: Stone expulsion RR (relative risk, the ratio of event probabilities between groups) 1.16 versus tamsulosin (95% CI, confidence interval — the range likely to contain the true value: 1.05 to 1.29) (Bai 2017); higher expulsion rate with tadalafil in an 11-trial update, OR (odds ratio, the ratio of odds between groups) 0.55 for tamsulosin versus tadalafil (95% CI 0.38 to 0.80) (Belkovsky 2023); no significant difference in expulsion rate or time versus tamsulosin (Montes Cardona 2017).

Medium 🟩 🟩

Fewer Cardiovascular Events and Lower All-Cause Mortality

Claims-database cohorts link tadalafil use to fewer major adverse cardiovascular events (MACE: heart attack, stroke, heart failure, revascularization (procedures to reopen blocked arteries), cardiovascular death) and lower all-cause mortality: Kloner (29,168 men with ED; lead author a paid consultant, unpaid for this study, to Sanofi, which holds Cialis over-the-counter rights per the Sanofi–Lilly press release) and Jehle (500,000+ men). A 16-cohort class meta-analysis agrees. No randomized outcome trial exists. Healthier men receive more prescriptions, a confounding (third factor driving both use and outcome) that a dose–response gradient partly argues against.

Magnitude: MACE HR (hazard ratio, the relative event rate over time) 0.81 (95% CI 0.70 to 0.94) and all-cause death HR 0.56 (95% CI 0.43 to 0.74) versus no PDE5 inhibitor (Kloner 2024); mortality RR 0.66 with tadalafil in men with ED (Jehle 2025); across PDE5 inhibitors, MACE RR 0.78 (95% CI 0.69 to 0.89) and mortality RR 0.70 (95% CI 0.56 to 0.87) (Soulaidopoulos 2024).

Prevention of High-Altitude Pulmonary Edema ⭕️ Not Central to Health & Longevity

In adults with prior high-altitude pulmonary edema (HAPE, fluid in the lungs caused by altitude-induced constriction of lung arteries), tadalafil 10 mg twice daily during rapid ascent to 4,559 m lowered pulmonary artery pressure and HAPE incidence in one small RCT led by Maggiorini (29 adults). It did not reduce acute mountain sickness, and two tadalafil users withdrew with severe mountain sickness. This bears on altitude travel, not on aging.

Magnitude: HAPE developed in 1 of 8 participants on tadalafil versus 7 of 9 on placebo (Maggiorini 2006).

Exercise Capacity in Pulmonary Arterial Hypertension ⭕️ Not Central to Health & Longevity

Tadalafil 40 mg daily is approved (as Adcirca) for PAH (Adcirca SmPC). The Lilly-sponsored PHIRST RCT led by Galiè (405 patients) improved walking distance and delayed clinical worsening; it is the single tadalafil-specific trial cited. A Cochrane review led by Barnes found the PDE5 inhibitor class improves walking distance, but pooled other agents. This bears on a specific disease, not on healthy aging.

Magnitude: Six-minute walk 33 m farther than placebo (95% CI 15 to 50 m) with 40 mg (Galiè 2009); across PDE5 inhibitors, 48 m farther (95% CI 40 to 56 m) (Barnes 2019).

Low 🟩

Glycemic Control ⚠️ Conflicted

In type 2 diabetes, daily tadalafil lowered HbA1c (glycated hemoglobin, a three-month blood-glucose average) in small placebo-controlled trials by Fryk (Lilly co-funded) and Lee. A larger Lilly trial of as-needed dosing (Sáenz de Tejada) found no change. Net reading: a possible small effect of daily dosing, unconfirmed.

Magnitude: HbA1c 2.50 mmol/mol lower than placebo (95% CI −4.20 to −0.78) (Fryk 2023); HbA1c −0.14% with tadalafil versus +0.20% with placebo over 6 months, group difference P = 0.030 (P, the probability that a difference this large arises by chance) (Lee 2022); mean HbA1c unchanged over 12 weeks of as-needed 10 or 20 mg, with no figure reported (Sáenz de Tejada 2002).

Vascular Function and Blood Pressure

PDE5 inhibition modestly lowers blood pressure and improves endothelial function. Evidence is indirect: a 63-trial meta-analysis led by Zhang pooled tadalafil with other PDE5 inhibitors, and tadalafil-specific data come from one small four-week trial and a single-dose study. Clinical-outcome impact is untested.

Magnitude: Across PDE5 inhibitors, systolic blood pressure 2.80 mmHg lower than placebo (95% CI −4.24 to −1.37) and FMD (flow-mediated dilation, an ultrasound measure of artery widening) 2.47% higher (95% CI 1.24 to 3.71) (Zhang 2025); tadalafil 20 mg every other day: FMD 4.2% to 9.3% versus 4.1% to 4.0% with placebo, not compared between groups (Rosano 2005); a single 20 mg dose lowered blood pressure by 7.8/4.9 mmHg versus placebo (Pauls 2022).

Lower Dementia Risk ⚠️ Conflicted

Cohorts comparing ED patients with non-users, open to healthy-user bias, link PDE5 inhibitor use to less dementia (Jehle; Adesuyan). A drug-versus-drug Medicare cohort (Desai) and a meta-analysis tadalafil subgroup (Abouelmagd 2024) found none; PASTIS (Pauls 2022) showed no significant brain blood-flow gain. Net reading: unconfirmed, weaker for tadalafil.

Magnitude: Dementia RR 0.68 with tadalafil (Jehle 2025); Alzheimer’s HR 0.82 (95% CI 0.72 to 0.93) across PDE5 inhibitors (Adesuyan 2024); no association, HR 0.99 (95% CI 0.69 to 1.43) (Desai 2022); no cognitive difference versus placebo after 3 months of 20 mg daily in a randomized trial in small vessel disease (damage to the brain’s smallest arteries) (Ölmestig 2025).

Lower Colorectal Cancer Risk

Two meta-analyses of observational studies link PDE5 inhibitor use to fewer colorectal cancers and advanced polyps (precancerous growths): Bhagavathula (4 studies, 965,044 people) and Cullinane (6 studies, 995,242 people). Evidence is indirect: tadalafil was pooled with other PDE5 inhibitors, and healthier men are more likely to be prescribed them.

Magnitude: Colorectal cancer or advanced polyps OR 0.88 (95% CI 0.79 to 0.98) in ever-users versus never-users, and colorectal cancer OR 0.85 (95% CI 0.75 to 0.95) in people without prior colorectal cancer (Cullinane 2023); RR 0.85 (95% CI 0.76 to 0.95) across all users (Bhagavathula 2021).

Fewer Raynaud’s Attacks ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Bears on Raynaud’s phenomenon (cold-triggered spasm of finger arteries), mostly secondary to scleroderma (autoimmune hardening of skin and vessels). A Cochrane review led by Maltez (4 of 9 trials tadalafil) found fewer attacks; Shenoy’s tadalafil trial was positive, Schiopu’s null. Net reading: a small, inconsistent benefit.

Magnitude: 3.07 fewer attacks per week than placebo across PDE5 inhibitors (95% CI −5.15 to −1.00) (Maltez 2023); no significant difference in attack frequency with tadalafil 20 mg daily (Schiopu 2009); as add-on therapy, fewer daily attacks than placebo, and all 24 digital ulcers (fingertip sores) healed on tadalafil versus 3 of 13 on placebo (Shenoy 2010).

Better Sperm Motility in Infertile Men ⭕️ Not Central to Health & Longevity

Bears on male fertility, not on aging. A meta-analysis led by Tan (11 studies, 1,317 participants) found single doses of PDE5 inhibitors raised the share of moving sperm in infertile men only. Evidence is indirect: tadalafil was pooled with other PDE5 inhibitors, and only acute dosing was tested.

Magnitude: Motile sperm 7.05 percentage points higher than control across PDE5 inhibitors (95% CI 2.59 to 11.51); 6.89 points in infertile men versus 0.67 (not significant) in men with normal fertility (Tan 2017).

Longer Ejaculatory Latency in Premature Ejaculation

In men with premature ejaculation (ejaculation sooner than wanted, causing distress), a meta-analysis of seven placebo-controlled trials (471 men) led by Zhang found PDE5 inhibitors lengthened time to ejaculation and improved sexual satisfaction. Evidence is indirect: tadalafil was pooled with other PDE5 inhibitors, and trial quality was limited.

Magnitude: Intravaginal ejaculatory latency (time from penetration to ejaculation) 2.60 minutes longer than placebo across PDE5 inhibitors (95% CI 1.85 to 3.36) (Zhang 2020).

Speculative 🟨

Reversal of Diabetic Heart Remodeling

In RECOGITO (122 adults with diabetic cardiomyopathy, heart-muscle damage from diabetes), daily 20 mg improved cardiac torsion (the heart’s twisting motion) in men only (Pofi 2022). These markers lack outcome validation.

Lower Vascular Inflammation Markers

A 20-trial meta-analysis led by Cianciarulo, pooling tadalafil with other PDE5 inhibitors, found long-term use lowered IL-6 and P-selectin (inflammation markers) (Cianciarulo 2025). These markers lack outcome validation.

Antitumor Immune Modulation ⭕️ Not Central to Health & Longevity

Bears on existing head and neck cancer, not on aging. Preoperative tadalafil lowered myeloid-derived suppressor cells (immune cells that shield tumors) and raised tumor-reactive T cells (Weed 2015). Only immune biomarkers were measured.

Benefit-Modifying Factors

  • Genetic polymorphisms: No validated genetic predictor of tadalafil benefit exists. Variants changing CYP3A4 or CYP3A5 (a related drug-clearing liver enzyme) activity could alter exposure but are untested; co-prescribed CYP3A4 inhibitors (drugs that slow its clearance) or inducers (drugs that speed it) matter more.
  • Baseline biomarkers: In tadalafil non-responders, added testosterone helped only when total testosterone was 3 ng/mL or lower (Buvat 2011). Glycemic benefits were shown only in type 2 diabetes, and urinary benefits in men with IPSS of 13 or higher.
  • Sex differences: ED and BPH benefits apply to men only. In RECOGITO, cardiac remodeling improved in men but not women (Pofi 2022). The dementia meta-analysis found no male–female difference in association (Abouelmagd 2024); PAH and Raynaud’s trials included women.
  • Pre-existing conditions: Severe ED responds less: 44.5% of men with severe ED reached a meaningful improvement on 5 mg versus 74.8% with mild ED (Porst 2014). Nerve damage after prostate surgery reduces response; diabetes still responds.
  • Age: Efficacy was similar in men over 65 in label trials (FDA label); older men clear the drug more slowly (about 25% higher exposure). Older men with both urinary symptoms and ED gain two benefits from one drug.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Headache, Flushing and Nasal Congestion

These vasodilatory effects (from widening of blood vessels in the head, face and nose) are the most common adverse events, usually mild and dose-related. Evidence comes from Lilly’s placebo-controlled trial program summarized in the label and a Cochrane review led by Barnes, which found more headache and flushing with PDE5 inhibitors. Rates are lower with daily 5 mg than with 20 mg on demand.

Magnitude: Headache 15% with 20 mg versus 5% with placebo, flushing 3% versus 1%, nasal congestion 3% versus 1% (FDA label); headache 6% with daily 5 mg versus 5% with placebo; headache OR 1.97 (95% CI 1.33 to 2.92) and flushing OR 4.12 (95% CI 1.83 to 9.26) across PDE5 inhibitors in PAH (Barnes 2019).

Dyspepsia and Reflux

Dyspepsia (indigestion) and gastroesophageal reflux arise because PDE5 inhibition relaxes the lower esophageal sphincter. Rates rise with dose. Evidence: Lilly’s controlled trials (label) and the Barnes Cochrane review showing more gastrointestinal upset. It is reversible and rarely causes discontinuation.

Magnitude: Dyspepsia 10% with 20 mg versus 1% with placebo; 2.4% with daily 5 mg versus 0.2% with placebo in BPH trials (FDA label); gastrointestinal upset OR 1.63 (95% CI 1.07 to 2.48) across PDE5 inhibitors (Barnes 2019).

Back Pain and Myalgia

Diffuse lower-back, buttock and thigh muscle pain (myalgia) typically starts 12–24 hours after a dose, worsens lying down, and resolves within 48 hours. It is more frequent with tadalafil than other PDE5 inhibitors, possibly via PDE11 inhibition. A Lilly-sponsored analysis led by Seftel found no muscle damage on imaging or blood tests; the Barnes review confirms excess muscle aches.

Magnitude: Back pain or myalgia in 8.3% on 20 mg versus 3.7% on placebo; 0.7% on 20 mg discontinued versus none on placebo (Seftel 2005); muscle aches OR 2.52 (95% CI 1.59 to 3.99) across PDE5 inhibitors (Barnes 2019).

Medium 🟥 🟥

Symptomatic Hypotension and Dizziness

Tadalafil alone lowers blood pressure only slightly, but it adds to the effect of alpha-blockers, antihypertensives (blood-pressure-lowering drugs) and heavy alcohol intake, causing dizziness or fainting on standing (orthostatic hypotension, a blood-pressure drop on standing up). Evidence: Lilly-sponsored clinical pharmacology studies led by Kloner and the label. Risk is greatest with doxazosin and in men with autonomic dysfunction (impaired nerve control of blood pressure) or low fluid volume.

Magnitude: Dizziness 1.0% with daily 5 mg versus 0.5% with placebo (FDA label); with doxazosin 8 mg, standing systolic pressure fell 9.8 mmHg more than with placebo (95% CI 4.1 to 15.5) (Kloner 2004).

Low 🟥

Reduced Sperm Concentration ⚠️ Conflicted

Lilly’s daily-dosing studies (label) found lower sperm concentration in two of three, without motility, shape or hormone changes; the label calls this not clinically meaningful. Hellstrom’s report of the two 6-month RCTs found no adverse effect, and Tan’s meta-analysis found none after acute dosing. Net reading: inconsistent and likely negligible.

Magnitude: Decreases occurred with 10 mg daily for 6 months and 20 mg daily for 9 months but not with 20 mg daily for 6 months; the label reports no outcome figure and calls the differences not clinically meaningful (FDA label); no adverse effect on sperm concentration versus placebo after 6 months of 10 or 20 mg daily (Hellstrom 2003); after acute dosing, pooled sperm-concentration mean difference 2.04 (95% CI −2.95 to 7.04) versus control, not significant (Tan 2017).

Sudden Vision Loss From Optic Nerve Ischemia ⚠️ Conflicted

NAION (non-arteritic anterior ischemic optic neuropathy, a sudden “stroke” of the optic nerve) is reported with PDE5 inhibitors. Evidence is indirect (drug class, not tadalafil alone): a self-controlled study funded by sildenafil maker Pfizer (Campbell) found doubled short-term risk; a Penedones meta-analysis found none. Net reading: a small possible risk.

Magnitude: OR 2.15 (95% CI 1.06 to 4.34) within five half-lives of use, compared with the same men’s earlier periods; estimated three added cases per 100,000 men over 50 per year with weekly use (Campbell 2015); OR 1.16 (95% CI 0.89 to 1.52) (Penedones 2020).

Sudden Sensorineural Hearing Loss

Sudden sensorineural (inner-ear or hearing-nerve) hearing loss, sometimes with tinnitus (ringing in the ears), is reported after PDE5 inhibitor use and listed in the label. Evidence is indirect: a claims cohort covered the drug class, not tadalafil alone. Recovery is often incomplete.

Magnitude: HR 1.25 (95% CI 1.01 to 1.55) during current PDE5 inhibitor use versus non-use; incidence 4.35 versus 2.38 per 10,000 person-years (one person followed for one year) (Liu 2018).

Melanoma ⚠️ Conflicted

Meta-analyses associate PDE5 inhibitor use with melanoma; evidence is indirect (drug class), and the tadalafil-only estimate was not significant (Kreuz). Loeb found the link limited to low exposure and early-stage disease, and present for basal cell cancer (a slow-growing skin cancer), suggesting sun-exposure confounding. Net reading: likely confounded, not excluded.

Magnitude: Melanoma OR 1.60 (95% CI 1.13 to 2.27) across PDE5 inhibitors; tadalafil OR 1.54 (95% CI 0.79 to 3.00) (Kreuz 2025); RR 1.11 (95% CI 1.02 to 1.22) without a dose–response pattern (Loeb 2017).

Cardiac Events Around Sexual Activity ⚠️ Conflicted

Heart attack, sudden cardiac death and stroke appear in postmarketing (after-approval) reports for tadalafil, often during sexual activity in men with risk factors (FDA label). A Lilly-sponsored analysis of 35 controlled trials, led by Jackson, showed no excess. Net reading: risk stems mainly from sexual exertion in vulnerable hearts.

Magnitude: Myocardial infarction (heart attack) 0.33 per 100 patient-years on tadalafil versus 0.41 on placebo (Jackson 2004).

Priapism

Priapism (an erection lasting over 4 hours, which can permanently damage erectile tissue) is rare. Evidence is case reports and spontaneous-report signals in the World Health Organization (WHO) database (Abbasi), strongest under age 18. Sickle cell disease (an inherited red-cell disorder) and penile deformity raise risk.

Magnitude: Not quantified in available studies. Only case reports and spontaneous-report analyses exist, which cannot yield an incidence (King 2005; Abbasi 2024).

Serious Skin and Hypersensitivity Reactions

Allergic reactions, including Stevens-Johnson syndrome (a severe skin and mucous-membrane reaction) and exfoliative dermatitis (widespread skin peeling), are reported postmarketing (FDA label). Case reports describe fixed drug eruptions (skin lesions recurring at the same site with each dose), some blistering and widespread. Frequency is unknown.

Magnitude: Not quantified in available studies. Only postmarketing and case reports exist, which cannot yield an incidence (Bjekic 2013; Sarawgi 2023).

Retinal Vascular Occlusion and Retinal Detachment

The label lists retinal vein and artery occlusion (blocked retinal blood vessels) and visual field defects among postmarketing reports (FDA label). A claims cohort led by Etminan linked regular PDE5 inhibitor use to retinal problems. Evidence is indirect: the cohort covered the drug class, not tadalafil alone.

Magnitude: Serous retinal detachment (fluid lifting the retina) IRR (incidence rate ratio, the ratio of new-case rates) 2.58 (95% CI 1.55 to 4.30) and retinal vascular occlusion IRR 1.44 (95% CI 0.98 to 2.12, not significant) in regular PDE5 inhibitor users versus nonusers; incidence among users 3.8 and 8.5 per 10,000 person-years respectively, nonuser rates not reported (Etminan 2022).

Seizures and Transient Global Amnesia

Seizure, seizure recurrence and transient global amnesia (a sudden, temporary inability to form new memories) are listed among postmarketing reports (FDA label). Evidence is limited to case reports, including amnesia after a first tadalafil dose. Causality is unproven.

Magnitude: Not quantified in available studies. Only postmarketing and case reports exist, which cannot yield an incidence (Schiefer 2005; Machado 2010).

Speculative 🟨

Testicular Effects of Chronic PDE11 Inhibition

Beagle dogs given tadalafil daily for 3–12 months developed irreversible testicular tubule degeneration; rats did not (FDA label). Basis is animal data only; no human testicular toxicity is documented.

Risk-Modifying Factors

  • Genetic polymorphisms: No validated pharmacogenetic risk marker exists. Hereditary degenerative retinal disorders such as retinitis pigmentosa (inherited retinal degeneration, sometimes involving PDE6 genes) were excluded from trials, and the label does not recommend use (FDA label).
  • Baseline biomarkers: Resting blood pressure below 90/50 mmHg, creatinine clearance (a kidney-filtering measure) below 30 mL/min, and severe hepatic impairment (Child-Pugh Class C, a liver-function score) raise risk of hypotension or drug accumulation (FDA label).
  • Sex differences: Cialis is not indicated for women (FDA label); pregnancy and lactation data are absent. In ETLAS-2, 46% of women versus 16% of men stopped daily 20 mg (Ölmestig 2025). Sperm-concentration effects apply to men.
  • Pre-existing conditions: Cardiovascular disease making sex inadvisable, aortic stenosis (narrowed heart valve), autonomic dysfunction, bleeding disorders, sickle cell disease or penile deformity (priapism), a “crowded” optic disc (small optic nerve head) or prior NAION, and personal melanoma history all raise specific risks.
  • Age: Men 65 or older have about 25% higher exposure and more diarrhea (2.5%) (FDA label). In older adults with small vessel disease, daily 20 mg caused adverse events in 76% versus 36% on placebo (Ölmestig 2025); older men also take more interacting alpha-blockers.

Key Interactions & Contraindications

Documented interactions:

  • Organic nitrates (heart drugs and inhalants that release nitric oxide: nitroglycerin, isosorbide mononitrate, inhaled amyl nitrite): Absolute contraindication. Severe, potentially fatal hypotension; the interaction persisted up to 24 hours after 20 mg. In emergencies, 48 hours should separate the last dose from nitrates (FDA label).
  • Guanylate cyclase stimulators (riociguat, a drug that directly boosts cGMP production): Absolute contraindication. Additive, potentially severe hypotension (FDA label).
  • Alpha-blockers (doxazosin, alfuzosin): Additive blood-pressure lowering, strongest with doxazosin; possible fainting. Avoid for BPH; for ED, the label specifies stability on the alpha-blocker before tadalafil is started at the lowest dose (FDA label; Kloner 2004).
  • Tamsulosin 0.4 mg: No interaction found; with tadalafil 10 or 20 mg, standing systolic pressure fell no more than with placebo (Kloner 2004).
  • Silodosin 8 mg: No interaction found; with a single tadalafil 20 mg dose, no clinically important orthostatic blood pressure or heart rate changes and no orthostatic symptoms versus placebo (MacDiarmid 2010).
  • Finasteride 5 mg: No new safety signal; in a Lilly-sponsored trial, tadalafil 5 mg added to finasteride for 26 weeks was well tolerated and improved urinary and erectile scores (Casabé 2014). The label limits combined initiation for BPH to 26 weeks (FDA label).
  • Antihypertensives (amlodipine, losartan, enalapril, metoprolol, bendrofluazide): Extra 3–8 mmHg systolic reduction; amlodipine 10 mg also raised tadalafil exposure 57%. Standing blood pressure checks after starting mitigate dizziness (FDA label; Kim 2022).
  • Strong CYP3A4 inhibitors (drugs that block tadalafil’s main clearing enzyme: ketoconazole, itraconazole, ritonavir, clarithromycin): Ketoconazole raised tadalafil exposure 312%, increasing adverse effects. Dose limited to 2.5 mg daily or 10 mg every 72 hours on demand (FDA label).
  • Grapefruit juice and erythromycin: The label states these CYP3A4 inhibitors would likely increase tadalafil exposure, raising the risk of headache, dizziness and low blood pressure; limiting grapefruit intake avoids this (FDA label).
  • CYP3A4 inducers (drugs that speed up the clearing enzyme: rifampin, carbamazepine, phenytoin, bosentan): Rifampin cut exposure 88% and bosentan 41.5% (Lilly study), reducing efficacy; no dose adjustment is labeled (FDA label; Wrishko 2008).
  • Alcohol (5 or more units): Orthostatic hypotension, dizziness, faster heart rate and headache; no interaction at lower intake (FDA label).
  • Other PDE5 inhibitors (sildenafil, vardenafil, Adcirca): Avoid. Additive hypotension and side effects; combinations are unstudied in the label (FDA label).
  • Supplements adulterated with tadalafil or analogs (“natural” sexual-enhancement capsules, honeys, chocolates): Hidden double dosing and nitrate-type hypotension risk; FDA testing repeatedly finds undeclared tadalafil (FDA tainted-products notice). Avoiding unregulated sexual-enhancement products removes this risk.
  • L-arginine (nitric oxide precursor): No harmful interaction reported; in men with diabetic ED, L-arginine plus tadalafil improved erectile scores more than either alone (El Taieb 2019), and both added to shockwave therapy outperformed shockwave alone (Gallo 2022).
  • Garlic (5 g twice daily): No harmful interaction reported; in a small randomized trial in poor responders, garlic added to tadalafil 5 mg improved erectile scores versus placebo (Bhat 2024). Blood pressure was not reported.
  • Over-the-counter antacids (magnesium/aluminum hydroxide) and H2 blockers (stomach-acid reducers such as nizatidine): No interaction found; antacids slowed absorption without changing total exposure (FDA label).
  • Aspirin: No interaction found; tadalafil 20 mg did not prolong aspirin’s effect on bleeding time (FDA label).
  • Warfarin, theophylline, digoxin, lovastatin, midazolam: No clinically significant interaction found; theophylline heart rate rose by 3 beats per minute (FDA label).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • L-citrulline (nitric oxide precursor): Inferred from additive NO-driven vasodilation; possible dizziness or low blood pressure. Spacing doses and checking standing blood pressure mitigate this.
  • Dietary nitrate supplements (beetroot juice or extract): Inferred from additive nitric oxide supply; possible hypotension at concentrated supplement doses. Ordinary vegetable intake is a far smaller nitrate load.
  • Blood-pressure-lowering supplements (hawthorn, high-dose magnesium): Inferred from additive blood pressure lowering; possible dizziness on standing. Standing blood pressure checks after starting either agent mitigate this.
  • Horny goat weed (icariin, a weak PDE5 inhibitor) and yohimbine: Inferred from additive PDE5 inhibition (icariin) and blood-pressure swings (yohimbine); possible excess side effects. Avoiding the combination removes the risk.
  • St. John’s wort: Inferred from CYP3A4 induction; likely lower tadalafil levels and reduced efficacy. Avoiding the combination, or reassessing response after starting it, mitigates this.
  • Pomegranate juice: Inferred from possible CYP3A4 inhibition reported in laboratory studies; possible higher tadalafil levels, with more headache, dizziness and low blood pressure. Limiting pomegranate juice intake mitigates this.
  • Sauna, hot baths and dehydration: Inferred from additive vasodilation and reduced blood volume; possible orthostatic dizziness. Hydration and slow standing mitigate this.

Populations who should avoid Tadalafil:

  • Users of any organic nitrate, regularly or intermittently, or of guanylate cyclase stimulators such as riociguat (contraindicated, FDA label)
  • Known serious hypersensitivity to tadalafil, including prior Stevens-Johnson syndrome (a severe skin and mucous-membrane reaction) or exfoliative dermatitis (widespread skin peeling) (contraindicated, FDA label)
  • Myocardial infarction (heart attack) within the last 90 days; unstable angina (chest pain from reduced heart blood flow) or angina during intercourse; NYHA (New York Heart Association, a heart-failure severity scale) Class 2 (symptoms with ordinary activity) or greater heart failure within 6 months; uncontrolled arrhythmias (irregular heart rhythms); hypotension below 90/50 mmHg or uncontrolled hypertension; stroke within 6 months (FDA label)
  • Men for whom sexual activity is inadvisable because of cardiovascular status (FDA label)
  • Severe hepatic impairment (Child-Pugh Class C); creatinine clearance below 30 mL/min or hemodialysis for daily use (FDA label)
  • Hereditary degenerative retinal disorders, including retinitis pigmentosa (FDA label)
  • Prior NAION, unless anticipated benefits outweigh the risk of recurrence (FDA label)
  • Women who are pregnant or breastfeeding: Cialis is not indicated for women and human data are absent (FDA label)
  • Personal history of melanoma: inferred from the observational melanoma association and proposed cGMP-linked growth signaling in pigment cells; no human evidence of harm in this group (Kreuz 2025)

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

  • Low starting dose: Starting at 2.5 mg daily and rising to 5 mg if tolerated (FDA label), typically after 1–2 weeks, limits headache, dyspepsia, back pain and dizziness, which are dose-related.
  • Nitrate emergency plan: Telling clinicians and family about tadalafil use prevents nitrate-induced collapse; at least 48 hours should separate the last dose from emergency nitrate use (FDA label).
  • Standing blood pressure checks: Measuring seated and standing blood pressure at baseline and 1–2 weeks after starting, or after adding an alpha-blocker or antihypertensive, detects orthostatic hypotension early.
  • Alcohol limit: Keeping intake below 5 units per occasion prevents alcohol-related orthostatic hypotension and dizziness (FDA label).
  • Interaction review: Checking every new prescription, antibiotic or antifungal for CYP3A4 effects prevents overexposure; with strong inhibitors the daily dose stays at 2.5 mg (FDA label).
  • Stop rules for vision, hearing and erections: Sudden vision or hearing loss means stopping tadalafil and seeking care immediately; an erection lasting over 4 hours needs emergency treatment to prevent permanent damage (FDA label).
  • Back pain management: Acetaminophen or an anti-inflammatory drug usually relieves tadalafil back pain, which typically resolves without treatment (FDA label).
  • Kidney and liver dose limits: With creatinine clearance 30–50 mL/min, starting daily BPH dosing at 2.5 mg prevents accumulation; below 30 mL/min daily use is not recommended (FDA label).
  • Annual skin examination: A yearly full-skin check, plus sun protection, addresses the possible melanoma association, especially with fair skin or prior skin cancer.
  • Licensed sourcing: Buying only from licensed pharmacies prevents counterfeit or adulterated products with unknown doses, a problem flagged by the UK Medicines and Healthcare products Regulatory Agency (MHRA) (MHRA press release).

Therapeutic Protocol

Timing, titration and cycling details below reflect common practice unless cited.

  • Longevity-oriented daily low dose: 2.5–5 mg once daily, the labeled daily ED and BPH doses (FDA label). Cardiologist Joel Kahn prescribes it daily (Kahn blog); AgelessRx markets a low-dose daily program (AgelessRx press release); neither publishes a dose rationale.
  • On-demand dosing: 10 mg before sexual activity, adjustable to 5 or 20 mg, at most once daily; effect lasts up to 36 hours (FDA label).
  • Daily versus on-demand: Daily dosing yielded 1.82 more IIEF points than on-demand, possibly not clinically meaningful (Bansal 2018). Integrative practitioners emphasize lifestyle and vascular measures alongside either regimen (Life Extension, which sells supplements: Life Extension protocol).
  • Research regimens: 20 mg every other day for endothelial function (Rosano 2005); 20 mg daily in diabetes trials (Fryk 2023; Pofi 2022); 40 mg daily for PAH (Galiè 2009).
  • Best time of day: The label specifies approximately the same time each day, with or without food. Back pain peaks 12–24 hours post-dose, so some users shift dosing to morning or evening to place symptoms conveniently.
  • Half-life: Mean 17.5 hours; steady state after about 5 days, with 1.6-fold accumulation. Effects therefore build over the first week and fade over several days after stopping (FDA label).
  • Single versus split dosing: A single daily dose suffices given the long half-life; the label advises against splitting tablets (FDA label).
  • Genetic polymorphisms: No pharmacogenetic dosing guidance exists; interacting CYP3A4 drugs, not genotype, drive dose limits in practice.
  • Sex differences: Cialis dosing applies to men; women receive tadalafil only for PAH (Adcirca, 40 mg daily) (Adcirca SmPC). No longevity dosing data exist for women.
  • Age: No label adjustment for age alone; men over 65 have about 25% higher exposure, and the labeled once-daily ED starting dose is 2.5 mg (FDA label).
  • Baseline biomarkers: Creatinine clearance 30–50 mL/min: start daily BPH dosing at 2.5 mg; below 30: avoid daily use; resting blood pressure below 90/50 mmHg: avoid (FDA label). Low testosterone predicts weaker erectile response.
  • Pre-existing conditions: Mild or moderate liver impairment (Child-Pugh A or B): on-demand dose at most 10 mg, daily use with caution; alpha-blocker users start at the lowest dose (FDA label).

Discontinuation & Cycling

  • Lifelong or short-term: Daily use for vascular or urinary aims is intended as long-term; benefits are maintained only while taking it. Endothelial improvement persisted 2 weeks after stopping (Rosano 2005).
  • Withdrawal effects: No withdrawal syndrome or dependence is documented; erectile and urinary symptoms return to baseline over several days as drug levels fall.
  • Tapering: Not required; tadalafil can be stopped abruptly because its long half-life provides a natural taper over 3–5 days.
  • Cycling: No trial has tested cycling, and loss of efficacy (tolerance) with continuous use is not documented; continuous daily dosing is the studied pattern.
  • Planned nitrate use or procedures: Stopping at least 48 hours before any planned nitrate exposure prevents dangerous hypotension (FDA label).

Sourcing and Quality

  • Regulated generic tablets: Generic tadalafil from licensed pharmacies contains the same active ingredient as Cialis (Eli Lilly), which the label lists in 5, 10 and 20 mg tablets (FDA label).
  • Counterfeits: Erectile-dysfunction medicines are a major counterfeiting target; the UK regulator seizes millions of pounds of unlicensed products yearly (MHRA press release). Online sellers not requiring a prescription carry high risk.
  • Adulterated supplements: “Natural” sexual-enhancement products often contain undeclared tadalafil or analogs at unknown doses (FDA tainted-products notice; ConsumerLab answer). These are not a substitute for regulated tadalafil.
  • What to look for: A verifiable licensed pharmacy (national pharmacy register), manufacturer name and lot number on packaging, and tablets matching the labeled imprint; third-party supplement seals do not apply to prescription drugs.
  • Compounded and combination products: Compounded chewables or troches combining tadalafil with other agents are not FDA-approved (FDA compounding Q&A); dose accuracy depends on the compounding pharmacy, and standard tablets make compounding unnecessary for most users.

Practical Considerations

  • Time to effect: Erectile effect within 30 minutes to 2 hours per dose; urinary symptoms improve within 1–4 weeks in a Lilly-sponsored trial (Porst 2011); endothelial changes by 4 weeks; HbA1c changes over 6 weeks to 6 months.
  • Common pitfalls: Expecting erections without sexual stimulation; judging efficacy after one dose; using amyl nitrite inhalants; combining with an alpha-blocker without blood pressure checks; buying online without prescription; overlooking that ED may signal cardiovascular disease.
  • Regulatory status: Prescription-only in the US, approved for ED and BPH (FDA label); licensed for PAH as Adcirca (Adcirca SmPC); UK pharmacy medicine since 2023 as Cialis Together 10 mg (MHRA press release). Longevity use is off-label.
  • Cost and research incentives: Generic tadalafil is inexpensive. Because neither manufacturers nor payers gain financially from proving longevity benefits of an inexpensive generic, long-term outcome trials lack funding; the evidence gap reflects missing investment more than negative results.

Interaction with Foundational Habits

  • Sleep: No direct effect. In men with BPH, reduced night-time urination may indirectly improve sleep continuity (potentiating); insomnia is rare (under 2%, FDA label). Back pain worsens lying down, so dosing time can be moved if pain disturbs sleep.
  • Nutrition: Food does not affect absorption (none). Grapefruit juice may raise levels via CYP3A4 (potentiating, FDA label); heavy alcohol adds hypotension. A Mediterranean-style diet supports the same vascular pathways (indirect); concentrated nitrate supplements may add vasodilation.
  • Exercise: Neutral to supportive. Tadalafil did not shorten time to ischemia in men with coronary disease (FDA label) and did not improve exercise capacity at altitude (Fischler 2009). Exercise independently improves erectile and vascular function (additive); hydration limits dizziness.
  • Stress management: No known effect on cortisol (none). In psychologically caused ED, 5 mg daily still improved erectile scores by 7.3 points (Porst 2014) (indirect, performance-anxiety relief), but it does not treat underlying stress; counseling remains complementary.

Monitoring Protocol & Defining Success

Before starting, a baseline assessment establishes safety and a reference point: a cardiovascular history and examination including seated and standing blood pressure, a review of all medications and supplements for nitrates, alpha-blockers and CYP3A4 drugs, kidney and liver function, and, for urinary symptoms, PSA (prostate-specific antigen) to exclude other prostate disease. Validated questionnaires for erectile and urinary function record the starting point, and HbA1c is useful for people with diabetes or prediabetes.

Ongoing monitoring follows this cadence: blood pressure and side-effect review at 1–2 weeks and 4 weeks after starting or after any dose change, questionnaires at 4–12 weeks, then kidney function, liver enzymes, HbA1c and blood pressure every 6–12 months, plus an annual skin examination. Sudden vision or hearing changes prompt immediate review rather than waiting for scheduled tests.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure (seated and standing) No established target; track standing drop versus own baseline Safety check: hypotension risk Label advises against use below 90/50 mmHg (FDA label); measure standing after 1–3 minutes; recheck after adding alpha-blockers
Creatinine clearance (from serum creatinine) Above 50 mL/min for standard dosing (FDA label) Safety check: dose limit 30–50 mL/min: start daily BPH dosing at 2.5 mg; below 30: no daily use (FDA label); conventional creatinine clearance reference range about 90–140 mL/min in adult men (laboratory-specific, declines with age)
Liver enzymes (ALT, AST) ALT about 7–55 U/L, AST about 8–48 U/L (standard reference range) Safety check: hepatic dose limits ALT and AST are alanine and aspartate aminotransferase (liver-cell enzymes); Child-Pugh scoring adds bilirubin, albumin and clotting time; no fasting needed
HbA1c About 4.0–5.6% (standard reference range) Expected to change: may fall modestly in diabetes Fasting not required; recheck after 3 months; effect shown in type 2 diabetes only
PSA About 0–4 ng/mL (standard reference range) Safety check: excludes prostate cancer before treating urinary symptoms Label advises considering other urological conditions before BPH treatment (FDA label); ejaculation or cycling within 48 hours before testing can raise PSA
IPSS questionnaire No established target; track change from own baseline Expected to change: urinary symptoms Scored 0–35; placebo-adjusted improvement about 2 points (Oelke 2012); repeat at 4–12 weeks
IIEF erectile-function score No established target; track change from own baseline Expected to change: erectile function Erectile-function domain scored 0–30; a 4-point gain is the minimal clinically important difference (Porst 2014)
Semen analysis (if planning conception) Sperm concentration at least 16 million/mL (standard reference range) Safety check: label reports reduced sperm concentration Lower reference limit from the World Health Organization WHO manual; 2–7 days abstinence before sampling

Qualitative markers of success and safety:

  • Erection quality, firmness and spontaneity
  • Night-time urination frequency and urinary stream
  • Headache, back pain and indigestion frequency
  • Dizziness or lightheadedness on standing
  • Any change in vision (including color tint) or hearing
  • Exercise tolerance and general energy

Emerging Research

  • Tadalafil in early Alzheimer’s disease (NCT07172815): Imperial College London phase 2, 244 participants with amyloid-positive (carrying Alzheimer’s-type brain deposits) mild cognitive impairment or early Alzheimer’s; one year of tadalafil versus placebo; primary endpoint safety, secondary cognition. Not yet recruiting. Positive results would strengthen the dementia item; null results would weaken it.
  • ETLAS-2 (NCT05173896): Phase 2, 76 patients with small vessel disease (damage to the brain’s smallest arteries); tadalafil 20 mg daily, 3 months. Results: lower adherence than placebo, adverse events 76% versus 36%, no cognitive benefit (Ölmestig 2025). Sub-studies run to 2029; positive perfusion data would revive the vascular rationale, null data would weaken it.
  • Tadalafil and mirabegron in prediabetes (NCT05051436): Phase 4, 96 adults, 14 weeks of tadalafil 10 mg, mirabegron (a bladder drug activating beta-3 receptors that switch on heat-producing brown fat) or both versus placebo; primary endpoint glucose tolerance. Recruiting. Positive results would extend glycemic benefit beyond diabetes; null results would confine it to diabetes.
  • Daily tadalafil in older adults with mild cognitive impairment (NCT07882901): Single-arm phase 2, 44 participants, 5 mg daily for 4 weeks; primary endpoint compliance, secondary brain-vessel reactivity and cognition. Not yet recruiting. Good tolerance would support larger trials; poor tolerance would limit daily use in frail elders.
  • Randomized mortality evidence: The mortality signals rest on cohorts (Kloner 2024; Jehle 2025); no randomized trial of cardiovascular or survival outcomes is registered, and such a trial would decide the central longevity question.
  • Melanoma causality: Updated pooling still shows a class association (Kreuz 2025), whereas causality criteria are unmet (Loeb 2017); exposure-response studies with sun-exposure adjustment could strengthen or remove this risk.
  • Brain perfusion trials: A single 20 mg dose did not significantly raise subcortical blood flow (Pauls 2022); longer dosing studies may reveal whether the dementia signal has a vascular basis.

Conclusion

Tadalafil is a long-acting, inexpensive generic drug that strengthens the body’s own blood-vessel-relaxing signal. For health-focused adults, its firmest benefits are better erectile function and easier urination in men with an enlarged prostate, both supported by many controlled trials. Evidence on blood sugar control in type 2 diabetes is mixed. The drug also helps in specific conditions such as lung-artery high blood pressure, kidney stone passage and lung fluid buildup at high altitude.

The longevity case rests mainly on large health-record studies in which men using tadalafil had fewer heart attacks, strokes and deaths. These findings are consistent, but no trial that assigned people at random has tested survival, and healthier men are more likely to receive prescriptions. Links to lower dementia risk are mixed and weaker for tadalafil than for related drugs.

Common side effects are headache, indigestion, flushing and back pain, mostly mild and dose-related. Rare but serious concerns include dangerous blood pressure drops with nitrate heart medications, sudden vision or hearing loss, and a possible link to skin cancer that may reflect sun exposure rather than the drug.

Much of the effectiveness evidence comes from manufacturer-sponsored trials, one major mortality study was led by a consultant to a company seeking to sell the drug without prescription, and a key eye-safety study was funded by a rival manufacturer. Because the drug is inexpensive and off-patent, no long-term survival trial has been funded, leaving the broader longevity claim plausible but unproven.

Top - Benefits - Risks - Protocol